3 registrations that name rutin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
RecruitingNCT07689214
Normast3 for Adults With Diabetic Polyneuropathy
No phase
University of Roma La Sapienza
About 40 people
Started Jul 17, 2024
In plain words A study of rutin in people 18 to 80, run by University of Roma La Sapienza. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Diabete Type 2.
What it tests, as registered
Normast® 3 - a food for special medical purposes (FSMP) containing co-micronized palmitoylethanolamide (PEA) with rutin and hydroxytyrosol. It is designed to support the management of diabetic polyneu; Placebo
Registered summary
The goal of this clinical trial is to find out if a new supplement called Normast® 3 can help reduce nerve pain and improve nerve function in adults with diabetic polyneuropathy (DPN). DPN is a common complication of diabetes that damages nerves, often causing burning, tingling, or stabbing pain, as well as problems with the autonomic nervous system, which controls things like sweating and heart rate. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT06916494
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
Phase 1
First Affiliated Hospital of Chongqing Medical University
About 10 people
Starts May 1, 2025 (estimated)
In plain words A Phase 1 study of rutin in people 18 and older, run by First Affiliated Hospital of Chongqing Medical University. It plans to enroll about 10 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Muscle Invasive Bladder Cancer.
Patients with cT2-cT4N0M0 muscle-invasive bladder cancer (MIBC)
No response after 2 cycles of GC neoadjuvant chemotherapy
No prior use of systemic immunotherapy or target therapy
Tumor is measurable according to New response evaluation criteria in solid tumours: Revised RECIST guideline
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Rutin; Gemcitabine, Cisplatin; Tislelizumab
Registered summary
This trial aims to evaluate the efficacy, safety, and biological mechanisms of rutin combined with tislelizumab and GC(Gemcitabine and Cisplatin) in platinum-refractory muscle-invasive bladder cancer patients. Key research questions include: 1. Whether rutin regulates epigenetic mechanisms in tumor cells from platinum-refractory bladder cancer patients and modulates the tumor immune microenvironment. 2. Evaluating the safety and adverse events of the combination treatment in platinum-refractory bladder cancer patients. 3. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07310407
Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Phase 2
Ain Shams University
About 120 people
Starts Jan 1, 2026 (estimated)
In plain words A Phase 2 study of rutin in people 18 to 65, run by Ain Shams University. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: NAFLD.
Confirmed diagnosis of Metabolic-Associated Steatotic Liver Disease (MASLD).
The exclusion criteria are on the listing.
What it tests, as registered
Rutin + Vitamin C; Vitamin C 500mg; Lifestyle Intervention
Registered summary
evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD